Microbicides
Microbicides
CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 08 March 2017 00:00
- Written by Gus Cairns
Research presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle found that the efficacy of oral pre-exposure prophylaxis (PrEP) for women was not affected by bacterial vaginosis (BV) -- the overgrowth in the vagina of untypical microbes. The effectiveness of PrEP in the Partners PrEP study was not significantly different in women with and without BV. This rules out BV as a possible cause for the lower effectiveness of oral PrEP in some studies of women compared to studies of men who have sex with men.
HIVR4P 2016: New Microbicide Enema Achieves High Levels of Drug in Rectal Tissues in Monkeys
- Details
- Category: Microbicides
- Published on Saturday, 22 October 2016 00:00
- Written by Gus Cairns
Rectal microbicides that protect against HIV transmission via anal sex are a bigger technical challenge than vaginal ones. The rectal lining is more delicate than the vaginal lining, so safety has been an issue; research has shown that many of the gel formulations used in lubricants damage rectal cells and may actually enhance HIV transmission.
NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Tuesday, 15 March 2016 00:00
- Written by NIAID
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, will support an open-label continuation study of the dapivirine vaginal ring that demonstrated modest protection against HIV infection, especially among older women, in 2 clinical trials in Africa, as reported at the recent Conference on Retroviruses and Opportunistic Infections in Boston.
Coverage of HIV Research for Prevention Conference (HIVR4P 2016)
- Details
- Category: HIV Prevention
- Published on Saturday, 22 October 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 HIV Research for Prevention Conference (HIVR4P 2016), October 17-21, in Chicago.
Conference highlights include current and experimental pre-exposure prophylaxis (PrEP), microbicide rings and other options, and investigational HIV vaccines.
Full listing of coverage by topic
10/22/16
CROI 2016: Maraviroc May Work as PrEP in a Combination, but Probably Not Alone
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 04 March 2016 00:00
- Written by Gus Cairns
Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston outlined the first findings from the NEXT-PrEP study, otherwise known as HPTN 069. What NEXT-PrEP has discovered so far indicates that the drug maraviroc (Selzentry) could have a role in pre-exposure prophylaxis, or PrEP, when used alongside either tenofovir or emtricitabine (the component drugs in Truvada), but is not potent enough to act as PrEP by itself.
More Articles...
- CROI 2016: Studies Look at Condom Use in IPERGAY French PrEP Trial
- CROI 2016: On-Demand Rectal Microbicide Gel Has Reasonable Acceptability -- Daily Less So
- ICAAC 2015: Combination Vaginal Ring May Be Able to Prevent Both HIV and Herpes
- Study Sheds Light on How Tenofovir is Processed in Different Body Tissues
Web Design and Development by